Insider trade

10% owner sold ~$2K of JNJ shares in the open market

Traded Nov 7, 2025 · Filed Nov 10, 2025

Johnson & JohnsonJNJ

~$2K
Reported value · 200 sh @ $10.00: 4.05M
Holds after · shares reported: +38.6%
stock since the trade · S&P 500 +13.9%, $186.57 → $258.66 on Oct 1

Why it stands out

A big owner of Johnson & Johnson sold $2K of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 7, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 10, 2025

10% ownerIndirect holding<$25K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,000

Shares × reported transaction price

Timing vs results

24 days after results of Oct 14, 2025, 75 days before results of Jan 21, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $186.57 on Nov 7, 2025, within 4% of its 52-week high, after a 4% rise over the previous 30 trading days

52-week range $142.06 (Jan 10, 2025) to $193.72 (Oct 20, 2025), 86% of the way up, from 250 adjusted closes. 30 trading days earlier: $179.71 on Sep 26, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Darzalex Faspro on Nov 6, 2025, 1 day before this trade.

New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.2%	-3.4%	+6.5%
30 days	+8.3%	+0.9%	+7.5%
90 days	+23.1%	+1.6%	+21.5%
180 days	+14.2%	+8.2%	+6.0%

Past results only. Not a forecast.

Source receipt

Record ID: 0001193125-25-274067
Filed / recorded: Nov 10, 2025, 8:28 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Needs review
Issuer: CVRx, Inc.
Issuer CIK: 1235912
Ticker: CVRX
Reporting person: JOHNSON & JOHNSON
Relationship: 10% owner
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 7, 2025
Transaction code: S
Shares / units: 200
Price per share: $10.00
Acquired / disposed: Disposed (D)
Shares owned after: 4,050,898
Ownership form: Indirect — By Johnson & Johnson Innovation - JJDC, Inc.
Amendment: No

Footnotes from the filing

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

Around the same time

10mo ago

Congress trade

$1,001 - $15,000Reported range · official band, not an exact amount

8 different filers disclosed JNJ within 90 days. Disclosed 34 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

Major shareholder sold10mo ago

~$64KReported value · 6,337 sh @ $10.03

A big owner of Johnson & Johnson sold $64K of Johnson & Johnson shares. Nobody planned it ahead of time.

Why it stands out Official record

Director bought10mo ago

~$258KReported value · 1,250 sh @ $206.15

A board member of Johnson & Johnson spent $258K of their very own money to buy Johnson & Johnson shares. Their pile of Johnson & Johnson shares grew by 209%.

Why it stands out Official record